EAT is up +49.38%% since April’24 pick View All Top Buy Picks

Latest Data & Signals Issued

Signal Type Signal Value Data
Score -1.756 4 days ( 1.11 % )
Last Price $0.0889 0.452 %
High/ Low $0.0889 - $0.0889 -1.12%
Chg 7 Days -1.11 % $0.0899 $0.0889
Chg 30 Days -8.88 % $0.0976 $0.0889
Chg 12 mos 83.30 % $0.0485 $0.0889
Trend - 3 mos -40.46 % Width: 102.77 %
Trend - 12 mos 10.81 % Width: 259.45 %
Pred. range - 3 mos $0.0227 - $0.0460 -74.46 % - -48.22 %
Pred. range - 12 mos $0.0748 - $0.269 -15.84 % - 202.50 %
Short MA avg 3 mos Sell Jun 18, 2024 - 6 days
Long MA avg 3 mos Sell Jun 03, 2024 - 17 days
Short/Long MA avg 3 mos Sell Jun 04, 2024 - 16 days
Short MA avg 12 mos Sell Jun 03, 2024 - 17 days
Long MA avg 12 mos Sell Apr 04, 2024 - 58 days
Short/Long MA avg 12 mos Sell Apr 05, 2024 - 57 days
Pivot Short Sell Jun 20, 2024 - 5 days
Bollinger Buy Nov 30, -1 - N/A days
MACD Buy No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About Nascent Biotech, Inc.

Nascent Biotech. Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platfo... NBIO Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT